Sign In
Buy NVO
$47.42
+1.52 (+3.31%)
At Close: Jun 23, 2026
Why Hims & Hers Health (HIMS) Stock Is Surging In Thursday's Premarket
09:13am, Thursday, 12'th Mar 2026
HIMS stock jumps in Thursday premarket. Explore how the Novo Nordisk partnership and a 46% short float are driving Hims and Hers Health Inc (NYSE: HIMS) higher.
Novo Nordisk stock slump hits value of controlling shareholder
08:12am, Thursday, 12'th Mar 2026
Novo Nordisk (NVO, Financials) has witnessed its share price plummet over the previous year, reducing the value of its largest shareholder's holdings.Novo Holdi
Novo Nordisk A/S $NVO Shares Sold by Capital International Sarl
04:08am, Thursday, 12'th Mar 2026
Capital International Sarl lessened its position in Novo Nordisk A/S (NYSE: NVO) by 80.7% during the third quarter, according to its most recent 13F filing with the SEC. The institutional investor own
Novo Holdings announces 2025 Annual Results
03:00am, Thursday, 12'th Mar 2026
Total Income and Investment Returns in 2025 were DKK 21 billion (€2.8 billion). For 2025, Total Income and Investment Returns consisted of Income from dividends from the Novo Group companies (DKK 15
India warns drugmakers against direct or surrogate weight-loss drug and obesity ads
03:26pm, Wednesday, 11'th Mar 2026
India's drug regulator has warned pharmaceutical companies against direct or indirect advertising of weight-loss medicines, including obesity awareness campaigns that could act as surrogate promoti
Hims & Hers: The Novo Nordisk Deal Changes Everything
12:15pm, Wednesday, 11'th Mar 2026
The Novo Nordisk partnership legitimizes Hims & Hers' business model by replacing compounded GLP-1 sales with branded Wegovy and Ozempic distribution. Hims generated $2.35B revenue in 2025 (+59% YoY)
This Novo Nordisk Partnership Shows That HIMS Has All The Leverage
10:40am, Wednesday, 11'th Mar 2026
Hims & Hers (HIMS) is still a Strong Buy, given that the transformative partnership with Novo Nordisk resolves legal risks and unlocks new growth avenues. HIMS' core value lies in its 2.5M+ cash-pay c
Can Novo Nordisk's Hims & Hers Deal Revive Its GLP-1 Momentum?
10:25am, Wednesday, 11'th Mar 2026
NVO partners with HIMS to expand access to Ozempic and Wegovy via telehealth, aiming to shift patients from compounded GLP-1s to FDA-approved drugs.
Ozempic Maker Novo Nordisk Faces Another Strike By US FDA With Warning Letter Over 'Systemic Failures' In Safety Reporting
02:27am, Wednesday, 11'th Mar 2026
US FDA hits Novo Nordisk with a "third strike" warning over "serious violations" in reporting Ozempic safety data, including deaths, strokes.
INVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Novo Nordisk A/S - NVO
04:47pm, Tuesday, 10'th Mar 2026
NEW YORK, March 10, 2026 (GLOBE NEWSWIRE) -- Pomerantz LLP is investigating claims on behalf of investors of Novo Nordisk A/S (“Novo Nordisk” or the “Company”) (NYSE: NVO). Such investors ar
Asset Manager Exits Shares of Hims & Hers Health
04:07pm, Tuesday, 10'th Mar 2026
Hims and Hers Health has struggled, but it just inked a new partnership with Novo Nordisk.
Novo Nordisk Warned by FDA Over Adverse Event Reporting
03:04pm, Tuesday, 10'th Mar 2026
Novo Nordisk (NVO, Financials) has received a warning letter from the U.S. Food and Drug Administration after the agency said the company failed to comply with
Patience Pays: Hims & Hers Surges on News of Novo Nordisk Deal
02:03pm, Tuesday, 10'th Mar 2026
After falling 59% from its year-to-date (YTD) high, embattled healthcare stock Hims & Hers Health NYSE: HIMS is making headlines as shares are surging in the wake of an agreement with GLP-1 maker Novo
GLP-1 weight-loss drug race heats up as new rival matches Wegovy results with fewer side effects
12:48pm, Tuesday, 10'th Mar 2026
Citi stays 'neutral' on Novo Nordisk as crowded obesity market threatens to erode its competitive edge Novo Nordisk (NYSE:NVO), the Danish pharma giant behind the Ozempic and Wegovy weight-loss drugs,
FDA Warns Novo Nordisk Over Potential Unreported Ozempic Side Effects, Deaths
12:45pm, Tuesday, 10'th Mar 2026
Weight loss drug giant Novo Nordisk has received a warning letter from the U.S. Food and Drug Administration for failing to report side effects potentially linked to Ozempic usage, including two death
